The immune system can specifically identify and eliminate cancerous or pre-cancerous cells by recognizing mutations or ligands related to stress, a process known as tumour immune surveillance (Smyth 2007).
These receptors can become aberrantly activated due to significant receptor overexpression, mutations, or ligand-dependent receptor dimerization [ 32, 33].
For example, the hedgehog signaling pathway, of vital importance in nervous system development, is hyperactivated either by mutation or by ligand overexpression in a significant percentage of human cancers [ 8].
Neither the SRC-1 null mutation nor ligand treatment affected the histopathologic pattern of these tumors.
Although there are specific examples that run counter to this argument, by and large it appears that EphA receptors, while being highly expressed in many cancers, are relatively kinase-inactive due to either kinase inactivating mutations or low ligand expression (Pasquale, 2010).
The region (15 24) of Aβ is of interest since the KLVFF motif included in this region is capable of binding to full-length Aβ [7], [8] and to the KLVFF motif itself [9], [10], and stabilization of this region in an α-helical conformation by mutations or by ligands counteracts Aβ polymerization into toxic assemblies [17], [19].
In tumors these receptors are activated by increased expression or structural rearrangement of receptor gene, mutation in ligand binding or tyrosine kinase domain or by the production of autocrine and paracrine ligands.
The combined use of molecular dynamics free energy simulations to study one binding process thoroughly, followed by molecular dynamics and Poisson-Boltzmann free energy calculations to study a series of related ligands or mutations is proposed as a paradigm for protein or ligand design.
Although the mutated residue does not form direct contacts with the ligand, the mutation increases ligand affinity by a factor of eight.
